Kadmon Holdings

General Information

We are a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, through in-licensing products and employing our small molecule and biologics platforms.

Employees: 138
Founded: 2010
Contact Information
Address 450 East 29th Street, New York, NY 10016, US
Phone Number (212) 308-6000
Web Address http://www.kadmon.com
View Prospectus: Kadmon Holdings
Financial Information
Market Cap $538.4mil
Revenues $37.7 mil (last 12 months)
Net Income $-151.9 mil (last 12 months)
IPO Profile
Symbol KDMN
Exchange NYSE
Shares (millions): 6.3
Price range $12.00 - $12.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Jefferies
CO-Managers JMP Securities/ H.C. Wainwright & Co.
Expected To Trade: 7/26/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change